HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.

AuthorsPhilip J Kahn, Randy Q Cron
JournalThe Journal of rheumatology (J Rheumatol) Vol. 40 Issue 5 Pg. 743-4 (May 2013) ISSN: 0315-162X [Print] Canada
PMID23637382 (Publication Type: Case Reports, Letter)
Chemical References
  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Interleukin 1 Receptor Antagonist Protein
Topics
  • Antirheumatic Agents (therapeutic use)
  • Child
  • Dose-Response Relationship, Drug
  • Drug Substitution
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Macrophage Activation Syndrome (drug therapy, pathology)
  • Remission Induction
  • Treatment Failure
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: